Boston Scientific Corp. (NYSE:BSX)

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

Segment Profit Margin: MedSurg

Boston Scientific Corp.; MedSurg; segment profit margin calculation

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Selected Financial Data (US$ in millions)
Operating income	1,625)	1,524)	1,156)	—)	—)
Net sales	5,057)	4,616)	3,844)	—)	—)
Segment Profitability Ratio
Segment profit margin¹	32.13%	33.02%	30.07%	—	—

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

¹ 2022 Calculation
Segment profit margin = 100 × Operating income ÷ Net sales
= 100 × 1,625 ÷ 5,057 = 32.13%

The MedSurg segment demonstrates a consistent upward trajectory in both top-line revenue and operating profitability over the observed three-year period from 2020 to 2022.

Net Sales Growth: A sustained increase in revenue is observed, with net sales rising from 3,844 million USD in 2020 to 5,057 million USD in 2022. This represents a steady expansion of the segment's financial scale.
Operating Income Expansion: Operating income grew in absolute terms each year, increasing from 1,156 million USD in 2020 to 1,625 million USD in 2022. The most pronounced growth occurred between 2020 and 2021, coinciding with a period of significant margin improvement.
Segment Profit Margin Trends: The segment profit margin experienced an initial expansion, rising from 30.07% in 2020 to a peak of 33.02% in 2021. A marginal contraction followed in 2022, with the margin adjusting to 32.13%. This indicates that while absolute operating income continued to rise in 2022, the growth rate of operating expenses slightly exceeded the growth rate of net sales during that period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

Segment Profit Margin: Cardiovascular

Boston Scientific Corp.; Cardiovascular; segment profit margin calculation

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Selected Financial Data (US$ in millions)
Operating income	2,113)	1,888)	1,043)	—)	—)
Net sales	8,161)	7,212)	5,913)	—)	—)
Segment Profitability Ratio
Segment profit margin¹	25.89%	26.18%	17.64%	—	—

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

¹ 2022 Calculation
Segment profit margin = 100 × Operating income ÷ Net sales
= 100 × 2,113 ÷ 8,161 = 25.89%

The Cardiovascular segment demonstrated significant growth in both scale and profitability between 2020 and 2022, characterized by a strong expansion of operating margins alongside increasing revenue.

Revenue Trends: Net sales exhibited a consistent upward trajectory, increasing from US$ 5,913 million in 2020 to US$ 8,161 million in 2022. This steady growth indicates a sustained increase in the segment's market presence or volume of sales over the observed period.
Operating Income Expansion: Operating income grew more rapidly than net sales, rising from US$ 1,043 million in 2020 to US$ 2,113 million in 2022. The most significant surge occurred between 2020 and 2021, where operating income increased by approximately 81%, suggesting a period of rapid operational scaling or effective cost management.
Segment Profit Margin Analysis: The segment profit margin improved sharply from 17.64% in 2020 to 26.18% in 2021. Although a marginal decline to 25.89% was observed in 2022, the margin remained substantially elevated compared to 2020 levels. This pattern suggests that the segment achieved significant operating leverage and efficiency gains that were largely sustained into 2022.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

Boston Scientific Corp., ROA by reportable segment

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
MedSurg	64.97%	69.97%	58.03%	—	—
Cardiovascular	40.60%	42.74%	26.51%	—	—

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

The analysis of Segment Return on Assets (ROA) between 2020 and 2022 indicates a period of growth followed by a slight stabilization across both reporting segments. Both MedSurg and Cardiovascular experienced a peak in asset efficiency during the 2021 fiscal year before seeing a marginal decline in 2022.

MedSurg Segment Performance: The MedSurg segment exhibited a strong ROA, beginning at 58.03% in 2020 and rising to 69.97% in 2021. A subsequent decrease to 64.97% in 2022 was observed, although the segment continued to maintain high efficiency in generating returns from its asset base.
Cardiovascular Segment Performance: The Cardiovascular segment showed a more pronounced relative increase in asset efficiency, with ROA ascending from 26.51% in 2020 to 42.74% in 2021. This was followed by a slight correction to 40.60% in 2022, suggesting a sustained improvement over the initial 2020 levels.
Comparative Segment Efficiency: A consistent performance gap is evident, as the MedSurg segment maintained a significantly higher ROA than the Cardiovascular segment throughout the analyzed period. However, the synchronized peak in 2021 and the subsequent slight decline in 2022 suggest that both segments were influenced by similar operational or macroeconomic drivers.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

Segment ROA: MedSurg

Boston Scientific Corp.; MedSurg; segment ROA calculation

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Selected Financial Data (US$ in millions)
Operating income	1,625)	1,524)	1,156)	—)	—)
Total assets	2,501)	2,178)	1,992)	—)	—)
Segment Profitability Ratio
Segment ROA¹	64.97%	69.97%	58.03%	—	—

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

¹ 2022 Calculation
Segment ROA = 100 × Operating income ÷ Total assets
= 100 × 1,625 ÷ 2,501 = 64.97%

The MedSurg segment demonstrated consistent growth in both operating income and its asset base between 2020 and 2022, although the efficiency of asset utilization experienced some volatility.

Operating Income Growth: Operating income increased steadily over the three-year period, rising from US$ 1,156 million in 2020 to US$ 1,524 million in 2021, and reaching US$ 1,625 million by December 31, 2022. This indicates a consistent upward trend in the segment's absolute profitability.
Asset Expansion: Total assets allocated to the segment grew concurrently, moving from US$ 1,992 million in 2020 to US$ 2,178 million in 2021, and further expanding to US$ 2,501 million in 2022. The steady increase in assets suggests ongoing investment in the segment's operational infrastructure.
Segment Return on Assets (ROA): The Segment ROA exhibited a fluctuating trend. After an initial increase from 58.03% in 2020 to a peak of 69.97% in 2021, the ratio moderated to 64.97% in 2022. The decrease observed in 2022 is the result of asset growth outpacing the growth in operating income during that period, which led to a slight reduction in overall asset efficiency despite the continued increase in total earnings.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

Segment ROA: Cardiovascular

Boston Scientific Corp.; Cardiovascular; segment ROA calculation

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Selected Financial Data (US$ in millions)
Operating income	2,113)	1,888)	1,043)	—)	—)
Total assets	5,205)	4,417)	3,934)	—)	—)
Segment Profitability Ratio
Segment ROA¹	40.60%	42.74%	26.51%	—	—

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

¹ 2022 Calculation
Segment ROA = 100 × Operating income ÷ Total assets
= 100 × 2,113 ÷ 5,205 = 40.60%

The Cardiovascular segment demonstrated a strong upward trajectory in profitability and asset efficiency from 2020 to 2022. While both operating income and total assets increased throughout the period, the rate of income growth significantly outpaced asset expansion in the initial phase, leading to a substantial peak in asset productivity.

Operating Income Growth: A consistent increase in operating income is observed, rising from 1,043 million USD in 2020 to 2,113 million USD by 2022. The most aggressive expansion occurred between 2020 and 2021, where income grew by approximately 81%, indicating a sharp improvement in the segment's operational profitability.
Asset Base Expansion: Total assets grew steadily over the three-year period, increasing from 3,934 million USD in 2020 to 5,205 million USD in 2022. This represents a cumulative increase of approximately 32%, suggesting ongoing investment in the segment's infrastructure or resource base.
Segment Return on Assets (ROA) Trends: The Segment ROA surged from 26.51% in 2020 to a peak of 42.74% in 2021, driven by the disproportionate growth of operating income relative to assets. In 2022, the ROA experienced a slight contraction to 40.60%. This marginal decline is attributable to the fact that asset growth in 2022 (17.8%) exceeded the growth rate of operating income (11.9%) for that same year.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

Boston Scientific Corp., asset turnover by reportable segment

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
MedSurg	2.02	2.12	1.93	—	—
Cardiovascular	1.57	1.63	1.50	—	—

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

An analysis of segment asset turnover from 2020 to 2022 reveals a synchronized performance pattern across both the MedSurg and Cardiovascular divisions. Both segments experienced a peak in asset utilization efficiency in 2021 before witnessing a moderate contraction in 2022.

MedSurg Segment Performance: The MedSurg segment demonstrated a strong asset turnover ratio, increasing from 1.93 in 2020 to a peak of 2.12 in 2021. This growth was followed by a slight decline to 2.02 in 2022, though the efficiency level remained higher than the 2020 baseline.
Cardiovascular Segment Performance: The Cardiovascular segment mirrored the trend of the MedSurg division, with the asset turnover ratio rising from 1.50 in 2020 to 1.63 in 2021. A subsequent decrease to 1.57 was observed in 2022, reflecting a similar trajectory of growth and slight correction.
Comparative Asset Efficiency: A consistent performance gap exists between the two segments, with MedSurg maintaining a significantly higher asset turnover ratio throughout the period. This indicates that the MedSurg segment is more efficient at generating revenue from its asset base compared to the Cardiovascular segment.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

Segment Asset Turnover: MedSurg

Boston Scientific Corp.; MedSurg; segment asset turnover calculation

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Selected Financial Data (US$ in millions)
Net sales	5,057)	4,616)	3,844)	—)	—)
Total assets	2,501)	2,178)	1,992)	—)	—)
Segment Activity Ratio
Segment asset turnover¹	2.02	2.12	1.93	—	—

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

¹ 2022 Calculation
Segment asset turnover = Net sales ÷ Total assets
= 5,057 ÷ 2,501 = 2.02

The MedSurg segment demonstrated consistent growth in both net sales and total assets from 2020 through 2022. Net sales increased from US$ 3,844 million in 2020 to US$ 5,057 million in 2022, representing a total growth of approximately 31.5%. During the same period, total assets grew from US$ 1,992 million to US$ 2,501 million, an increase of approximately 25.5%.

Segment Asset Turnover Trend: The asset turnover ratio exhibited a non-linear trajectory between 2020 and 2022. The ratio rose from 1.93 in 2020 to a peak of 2.12 in 2021, indicating an increase in the efficiency of asset utilization to generate revenue. However, the ratio declined slightly to 2.02 in 2022.
Asset Utilization Efficiency: The peak in 2021 suggests that revenue growth significantly outpaced the expansion of the asset base during that fiscal year. The subsequent dip in 2022 indicates that the growth in total assets began to catch up with or slightly exceed the rate of sales growth, although the 2022 efficiency level remains higher than the 2020 baseline.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

Segment Asset Turnover: Cardiovascular

Boston Scientific Corp.; Cardiovascular; segment asset turnover calculation

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Selected Financial Data (US$ in millions)
Net sales	8,161)	7,212)	5,913)	—)	—)
Total assets	5,205)	4,417)	3,934)	—)	—)
Segment Activity Ratio
Segment asset turnover¹	1.57	1.63	1.50	—	—

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

¹ 2022 Calculation
Segment asset turnover = Net sales ÷ Total assets
= 8,161 ÷ 5,205 = 1.57

The Cardiovascular segment exhibited consistent growth in both top-line revenue and its asset base from 2020 through 2022. Net sales experienced a steady upward trajectory, increasing from $5,913 million in 2020 to $8,161 million by the end of 2022. During the same period, total assets rose from $3,934 million to $5,205 million.

Net Sales Growth: Revenue expansion was significant over the observed period, with sales increasing by approximately 21.9% in 2021 and a further 13.1% in 2022, reflecting strong market demand or expanded capacity within the Cardiovascular segment.
Asset Base Expansion: Total assets grew steadily, increasing by 12.3% in 2021 and 17.8% in 2022. The acceleration in asset growth during 2022 suggests increased investment in the segment's infrastructure or resource base.
Segment Asset Turnover Efficiency: The asset turnover ratio, which measures the efficiency of generating sales from assets, improved from 1.50 in 2020 to 1.63 in 2021. This increase indicates that revenue growth outpaced asset accumulation during that fiscal year. However, the ratio declined slightly to 1.57 in 2022, as the rate of asset growth exceeded the rate of sales growth. Despite this minor retraction, the 2022 efficiency level remains superior to the 2020 baseline.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

Boston Scientific Corp., net sales by reportable segment

US$ in millions

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
MedSurg	5,057)	4,616)	3,844)	—)	—)
Cardiovascular	8,161)	7,212)	5,913)	—)	—)
Total reportable segments	13,218)	11,828)	9,757)	—)	—)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Total net sales across reportable segments exhibited a consistent upward trend from 2020 through 2022, increasing from US$ 9,757 million to US$ 13,218 million. This represents an overall growth of approximately 35.5% over the observed three-year period, with the most significant year-over-year acceleration occurring between 2020 and 2021.

Cardiovascular Segment Performance: The Cardiovascular segment remains the primary revenue driver, maintaining the largest share of total net sales. Revenue grew from US$ 5,913 million in 2020 to US$ 8,161 million in 2022, marking a total increase of 38% over the period. The growth rate peaked between 2020 and 2021 with a 22% increase, followed by a 13.2% increase in 2022.
MedSurg Segment Performance: The MedSurg segment demonstrated steady growth, with net sales rising from US$ 3,844 million in 2020 to US$ 5,057 million in 2022. This constitutes a total expansion of 31.6%. Similar to the Cardiovascular segment, the highest growth rate was observed between 2020 and 2021, where sales increased by approximately 19.8%.
Segment Contribution and Composition: The Cardiovascular segment's dominance in the revenue mix remained stable and slightly expanded, accounting for approximately 60.6% of total reportable segment sales in 2020 and increasing to 61.7% by 2022. Conversely, the MedSurg segment's contribution shifted from 39.4% in 2020 to 38.3% in 2022, indicating that the Cardiovascular segment grew at a slightly faster pace than the MedSurg segment during this interval.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

Boston Scientific Corp., operating income by reportable segment

US$ in millions

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
MedSurg	1,625)	1,524)	1,156)	—)	—)
Cardiovascular	2,113)	1,888)	1,043)	—)	—)
Total reportable segments	3,738)	3,412)	2,199)	—)	—)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

The combined operating income for reportable segments demonstrated a consistent upward trajectory between 2020 and 2022, increasing from US$ 2,199 million to US$ 3,738 million. This represents a substantial expansion in profitability across the analyzed business units over the three-year period.

MedSurg Segment Performance: The MedSurg segment experienced steady growth, with operating income rising from US$ 1,156 million in 2020 to US$ 1,625 million by the end of 2022. The most significant year-over-year increase occurred between 2020 and 2021, followed by a more moderate growth rate into 2022.
Cardiovascular Segment Performance: The Cardiovascular segment exhibited the most aggressive growth pattern. Operating income increased from US$ 1,043 million in 2020 to US$ 2,113 million in 2022. A sharp acceleration was observed in 2021, where income increased by approximately 81% compared to the previous year, establishing this segment as the primary contributor to total reportable operating income.
Aggregate Segment Trends: While both segments contributed to overall growth, the Cardiovascular segment transitioned from being the smaller of the two in 2020 to the dominant driver of profitability by 2022. The total reportable operating income growth was primarily fueled by the rapid scaling of the Cardiovascular division, supplemented by the consistent gains in the MedSurg division.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

Boston Scientific Corp., total assets by reportable segment

US$ in millions

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
MedSurg	2,501)	2,178)	1,992)	—)	—)
Cardiovascular	5,205)	4,417)	3,934)	—)	—)
Total reportable segments	7,706)	6,595)	5,926)	—)	—)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Total assets across reportable segments exhibited a consistent upward trend from 2020 through 2022, characterized by an accelerating pace of expansion in the final year of the observed period.

MedSurg Segment Asset Expansion: Assets within the MedSurg segment grew from US$ 1,992 million in 2020 to US$ 2,501 million by December 31, 2022. This growth reflects a steady increase, with the rate of expansion rising from approximately 9.3% between 2020 and 2021 to 14.8% between 2021 and 2022.
Cardiovascular Segment Asset Expansion: The Cardiovascular segment showed a more pronounced increase in asset value, rising from US$ 3,934 million in 2020 to US$ 5,205 million in 2022. The growth trajectory accelerated over the period, moving from a 12.3% increase in 2021 to a 17.8% increase in 2022.
Aggregate Segment Analysis: Total assets for all reportable segments increased from US$ 5,926 million in 2020 to US$ 7,706 million in 2022, representing a total increase of 29.7%. The Cardiovascular segment consistently functioned as the larger component of the asset base, maintaining a stable proportional share of approximately 67% of total reportable segment assets throughout the three-year period.

AI Ask an analyst for more